Scholarlink

Background <p>We used state-of-the-art high-resolution retinal imaging to explore the treatment (loading dose of aflibercept) of diabetic macular edema (DME) among treatment-naive patients. Swept-source (SS) OCT and OCT-Angiography (SS-OCTA) were performed, and a dichotomous analysis was conducted to compare responders and treatment-resistant patients (responsive and resistant). Furthermore, treatment responses were evaluated based on the subdivision of choroidal thickness.</p> Materials and methods <p>This prospective, noncomparative, interventional case series study examined the following biomarkers: best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), avascular area of the superficial plexus (AASP), avascular area of the deep plexus (AADP), and vessel density (VD). Data from the baseline and 4-month examinations were compared.</p> Results <p>Twenty-eight eyes from 25 patients were included. Significant improvements were observed in BCVA (0.7250 ± 0.23 to 0.3957 ± 0.21; p &lt; 0.000), CMT µm (339.04 ± 66.19 to 265.21 ± 55.75; p &lt; 0.000), CCT µm (221.71 ± 69.69 to 209.07 ± 70.92; p &lt; 0.000), VD (17.90 ± 7.82 to 15.35 ± 5.80; p &lt; 0.038), AASP µm<sup>2</sup> (235,374 ± 91,299 to 157,326 ± 77,815; p &lt; 0.000) and AADP µm<sup>2</sup> (996,335 ± 1,000,047 to 362,161 ± 277,225; p &lt; 0.000). Dichotomous analysis revealed that 15 patients were responsive (53.57%), and 13 resistant (46.43%). There were no significant differences between any of the pretreatment biomarkers. In the subdivision of choroidal thickness, which ranged from 211 to 270&#xa0;µm (group 3), we found greater reductions in the CCT, AADP and CD. The choroidal thickness ranged from 181 to 210&#xa0;µm (group 2): BCVA and AASP exhibited the greatest reductions.</p> Conclusion <p>BCVA, CMT, CCT, AASP, AADP and VD were improved after treatment. The pretreatment biomarkers did not predict treatment response between the responsive and resistant. Regarding choroidal stratification, values within the normal range of CCT showed the greatest reductions, indicating that these values may be more responsive to treatment. Notably, this is the first study to analyze biomarkers provided by SS OCT and OCTA, stratify the choroid, and perform a dichotomous analysis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prospective and dichotomous study of biomarkers with swept-source OCT and OCT-angiography in naive patients with diabetic macular edema

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月22日

查看全文
  • Marcussi Palata Rezende,
  • Fernanda Atoui Faria,
  • Daniel Prado Beraldo,
  • Julia Polido,
  • Rubens Belfort Jr.,
  • Thiago Cabral

摘要

Background

We used state-of-the-art high-resolution retinal imaging to explore the treatment (loading dose of aflibercept) of diabetic macular edema (DME) among treatment-naive patients. Swept-source (SS) OCT and OCT-Angiography (SS-OCTA) were performed, and a dichotomous analysis was conducted to compare responders and treatment-resistant patients (responsive and resistant). Furthermore, treatment responses were evaluated based on the subdivision of choroidal thickness.

Materials and methods

This prospective, noncomparative, interventional case series study examined the following biomarkers: best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), avascular area of the superficial plexus (AASP), avascular area of the deep plexus (AADP), and vessel density (VD). Data from the baseline and 4-month examinations were compared.

Results

Twenty-eight eyes from 25 patients were included. Significant improvements were observed in BCVA (0.7250 ± 0.23 to 0.3957 ± 0.21; p < 0.000), CMT µm (339.04 ± 66.19 to 265.21 ± 55.75; p < 0.000), CCT µm (221.71 ± 69.69 to 209.07 ± 70.92; p < 0.000), VD (17.90 ± 7.82 to 15.35 ± 5.80; p < 0.038), AASP µm2 (235,374 ± 91,299 to 157,326 ± 77,815; p < 0.000) and AADP µm2 (996,335 ± 1,000,047 to 362,161 ± 277,225; p < 0.000). Dichotomous analysis revealed that 15 patients were responsive (53.57%), and 13 resistant (46.43%). There were no significant differences between any of the pretreatment biomarkers. In the subdivision of choroidal thickness, which ranged from 211 to 270 µm (group 3), we found greater reductions in the CCT, AADP and CD. The choroidal thickness ranged from 181 to 210 µm (group 2): BCVA and AASP exhibited the greatest reductions.

Conclusion

BCVA, CMT, CCT, AASP, AADP and VD were improved after treatment. The pretreatment biomarkers did not predict treatment response between the responsive and resistant. Regarding choroidal stratification, values within the normal range of CCT showed the greatest reductions, indicating that these values may be more responsive to treatment. Notably, this is the first study to analyze biomarkers provided by SS OCT and OCTA, stratify the choroid, and perform a dichotomous analysis.